Blinatumoab公司
嵌合抗原受体
淋巴细胞白血病
免疫疗法
医学
美罗华
临床试验
造血干细胞移植
细胞因子释放综合征
白血病
免疫学
肿瘤科
抗体
移植
内科学
免疫系统
作者
David Kegyes,Ciprian Jitaru,Gabriel Ghiaur,Stefan O. Ciurea,Dieter Hoelzer,Ciprian Tomuleasa,Robert Peter Gale
出处
期刊:Blood Reviews
[Elsevier]
日期:2023-05-01
卷期号:59: 101042-101042
被引量:2
标识
DOI:10.1016/j.blre.2023.101042
摘要
About one-half of adults with acute B-cell lymphoblastic leukemia (B-ALL) who do not achieve molecular complete remission or who subsequently relapse are not cured by current chemo- or targeted therapies. Previously, the sole therapeutic option for such persons was a hematopoietic stem cell transplant. Recently, several immune therapies including monoclonal antibodies, bispecific T-cell engagers (BiTEs), antibody-drug conjugates (ADCs), and chimeric antigen receptor T-cells (CARs) have been shown safe and effective in this setting. In this manuscript, we summarize data on US FDA-approved immune therapies of advanced adult B-ALL including rituximab, blinatumomab, inotuzumab ozogamicin, tisagenlecleucel and brexucabtagene autoleucel. We consider the results of clinical trials focusing on efficacy, safety, and quality of life (QoL). Real-world evidence is presented as well. We also briefly discuss pharmacodynamics, pharmacokinetics, and pharmacoeconomics followed by risk-benefit analyses. Lastly, we present future directions of immune therapies for advanced B-ALL in adults.
科研通智能强力驱动
Strongly Powered by AbleSci AI